Comparing Treatments Using Quality-Adjusted Survival: The Q-TWiST Method

Abstract The quality of life of patients is an important component of evaluation of therapies. We present an overview of a statistical method called Q-TWiST (Quality-Adjusted Time Without Symptoms and Toxicity) which incorporates quality-of-life considerations into treatment comparisons. Multivariate censored survival data are used to partition the overall survival time into periods of time spent in a set of progressive clinical health states which may differ in quality of life. Mean health state durations, restricted to the follow-up limits of the clinical trial, are derived from the data and combined with value weights to estimate quality-adjusted survival. The methodology emphasizes treatment comparisons based on threshold utility analyses that highlight trade-offs between different health state durations; it is not intended to provide a unique result combining quality and quantity of life. We also describe three recent extensions of the methodology: covariates can be included using proportional hazard...

[1]  R. Gelber,et al.  A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. International Breast Cancer Study Group. , 1995, Statistics in medicine.

[2]  R. Salama IMMUNITY AND CYSTIC FIBROSIS. , 1965, Lancet.

[3]  M. Baum,et al.  EVALUATION OF QUALITY OF LIFE IN PATIENTS RECEIVING TREATMENT FOR ADVANCED BREAST CANCER , 1976, The Lancet.

[4]  R. Sanson-Fisher,et al.  Measuring quality of life in cancer patients. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Gelber,et al.  Evaluation of effectiveness: Q-TWiST , 1993 .

[6]  R. Gelber,et al.  Parametric approaches to quality-adjusted survival analysis. International Breast Cancer Study Group. , 1994, Biometrics.

[7]  P Glasziou,et al.  Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M A Fischl,et al.  Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. The AIDS Clinical Trials Group. , 1992, Annals of internal medicine.

[9]  N. Breslow,et al.  A Large Sample Study of the Life Table and Product Limit Estimates Under Random Censorship , 1974 .

[10]  Richard D. Gelber,et al.  A quality-of-life-oriented endpoint for comparing therapies. , 1989 .

[11]  David R. Cox,et al.  Quality‐Of‐Life Assessment: Can We Keep it Simple? , 1992 .

[12]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[13]  R. Gelber,et al.  Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. International Breast Cancer Study Group. , 1993, Controlled clinical trials.

[14]  R. Gelber,et al.  A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Volberding,et al.  Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. , 1994, The New England journal of medicine.

[16]  G. Torrance Measurement of health state utilities for economic appraisal. , 1986, Journal of health economics.

[17]  F. Cavalli,et al.  Quality-of-Life-Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer , 1991 .

[18]  M. Schumacher,et al.  Assessment of quality of life in clinical trials. , 1991, Statistics in medicine.

[19]  R. Gelber,et al.  Cox regression models for quality adjusted survival analysis. , 1993, Statistics in medicine.

[20]  P. Selby,et al.  Assessing quality of life in cancer patients. , 1989, British Journal of Cancer.

[21]  R. Gelber,et al.  Quality adjusted survival analysis. , 1990, Statistics in medicine.

[22]  R. Gelber,et al.  Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group). , 1992, Journal of the National Cancer Institute. Monographs.

[23]  C. Moinpour,et al.  Quality of life end points in cancer clinical trials: review and recommendations. , 1989, Journal of the National Cancer Institute.